Alzheimer s & Dementia,
Journal Year:
2019,
Volume and Issue:
15(6), P. 764 - 775
Published: May 18, 2019
Abstract
Introduction
Blood‐based
biomarkers
of
pathophysiological
brain
amyloid
β
(Aβ)
accumulation,
particularly
for
preclinical
target
and
large‐scale
interventions,
are
warranted
to
effectively
enrich
Alzheimer's
disease
clinical
trials
management.
Methods
We
investigated
whether
plasma
concentrations
the
Aβ
1–40
/Aβ
1–42
ratio,
assessed
using
single‐molecule
array
(Simoa)
immunoassay,
may
predict
positron
emission
tomography
status
in
a
longitudinal
monocentric
cohort
(N
=
276)
older
individuals
with
subjective
memory
complaints.
performed
hypothesis‐driven
investigation
followed
by
no‐a‐priori
hypothesis
study
machine
learning.
Results
The
receiver
operating
characteristic
curve
learning
showed
balanced
accuracy
76.5%
81%,
respectively,
ratio.
is
not
affected
apolipoprotein
E
(
APOE
)
ε4
allele,
sex,
or
age.
Discussion
Our
results
encourage
an
independent
validation
confirm
indication
that
via
Simoa,
improve
future
standard
care
trial
design.
Biomarkers in Neuropsychiatry,
Journal Year:
2019,
Volume and Issue:
1, P. 100005 - 100005
Published: Nov. 13, 2019
In
2018,
there
was
a
recent
shift
towards
biological
definition
of
Alzheimer's
disease
(AD),
based
on
biomarkers
measured
in
vivo
even
before
the
onset
clinical
dementia
symptoms.
No
single
biomarker
can
by
itself
accurately
diagnose
AD.
A
combination
assessed
through
imaging
and
cerebrospinal
fluid
(CSF)
yields
better
diagnostic
accuracy.
Although
amyloid
PET
CSF
levels
tau
deposits
are
increasingly
used
AD
trials
to
increase
confidence
enrolled
subjects,
routine
use
these
settings
is
still
premature
because
risk
overdiagnosis,
increased
cost
and/or
invasiveness
assessment
method.
Also,
standardization
measures
across
studies
needed
assure
regulatory
approval.
Exploring
novel
beyond
pathologies,
their
longitudinal
change
continnum
important
research
avenues
for
future.
New England Journal of Medicine,
Journal Year:
2024,
Volume and Issue:
390(8), P. 712 - 722
Published: Feb. 21, 2024
Biomarker
changes
that
occur
in
the
period
between
normal
cognition
and
diagnosis
of
sporadic
Alzheimer's
disease
have
not
been
extensively
investigated
longitudinal
studies.
Alzheimer s & Dementia,
Journal Year:
2019,
Volume and Issue:
15(6), P. 764 - 775
Published: May 18, 2019
Abstract
Introduction
Blood‐based
biomarkers
of
pathophysiological
brain
amyloid
β
(Aβ)
accumulation,
particularly
for
preclinical
target
and
large‐scale
interventions,
are
warranted
to
effectively
enrich
Alzheimer's
disease
clinical
trials
management.
Methods
We
investigated
whether
plasma
concentrations
the
Aβ
1–40
/Aβ
1–42
ratio,
assessed
using
single‐molecule
array
(Simoa)
immunoassay,
may
predict
positron
emission
tomography
status
in
a
longitudinal
monocentric
cohort
(N
=
276)
older
individuals
with
subjective
memory
complaints.
performed
hypothesis‐driven
investigation
followed
by
no‐a‐priori
hypothesis
study
machine
learning.
Results
The
receiver
operating
characteristic
curve
learning
showed
balanced
accuracy
76.5%
81%,
respectively,
ratio.
is
not
affected
apolipoprotein
E
(
APOE
)
ε4
allele,
sex,
or
age.
Discussion
Our
results
encourage
an
independent
validation
confirm
indication
that
via
Simoa,
improve
future
standard
care
trial
design.
